Jefferies Cuts Price Target on Regeneron (REGN) Following District Court Ruling
Get Alerts REGN Hot Sheet
Rating Summary:
29 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Jefferies maintained a Hold rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $349.00 (from $394.00), following a decision by the District Court of Delaware. Judge Sue Robinson at the District Court of Delaware ruled in favor of Amgen (NASDAQ: AMGN) on the permanent injunction against SAN.FP/REGN's Praluent.
Analyst Biren Amin commented, "The District Court of Delaware today ruled in favor of AMGN on the permanent injunction against SAN.FP/REGN's Praluent. While the public interest argument weighed in SAN.FP/REGN's favor, it was not enough to overcome other factors favoring AMGN. SAN.FP/REGN are likely to appeal, but there is precedence that the Appeals Court doesn't necessarily favor public interest arguments. We have removed Praluent from our model starting in 2018, lowering our PT to $349."
For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.
Shares of Regeneron Pharma closed at $380.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rentokil Initial (RTO) PT Lowered to $35 at Oppenheimer
- JMDC Inc (4483:JP) PT Lowered to JPY6,800 at Nomura/Instinet
- Boston Beer Company (SAM) PT Lowered to $310 at Evercore ISI
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, LitigationRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!